Advertisement

Immunological Aspects of the Toxic Oil Syndrome

  • Carlos Lahoz
  • Victoria del Pozo
  • Soledad Gallardo
  • Blanca Cárdaba
  • Aurora Jurado
  • Isabel Cortegano
  • Ana del Amo
  • Ignacio Arrieta
  • Pilar Palomino
Part of the Archives of Toxicology book series (TOXICOLOGY, volume 19)

Abstract

The Toxic Oil Syndrome (TOS), which occurred in Spain in 1981, was caused by the ingestion of rapeseed oil denatured with 2% aniline, sold illegally as edible oil. The number of unaffected individuals exposed to the toxic oil is unknown, but more than 20,000 people suffered from the disease.

Keywords

Juvenile Rheumatoid Arthritis SCD23 Level Eosinophilia Myalgia Syndrome Reverse Transcriptase Polymerase Chain Reaction Technique Reactive Drug Metabolite 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aguilera B (1989) Lesiones vasculares en el Síndrome Tóxico por aceite de colza. Doctoral Thesis, Madrid Universidad Autónoma 26–41.Google Scholar
  2. Bell SA, Hobbs MV, Rubin RL (1992) Isotype-restricted hyperimmunity in a murine model of the toxic oil syndrome. J. Immunol. 148: 3369–3376.PubMedGoogle Scholar
  3. Blasco R, Ruiz-Gutierrez V (1992) Effect of fatty acid anilides on immune responses of Swiss mice. Clin. Exp. Immunol. 89: 131–135.PubMedCrossRefGoogle Scholar
  4. De Andrés B, del Pozo V, Gallardo S, de Arruda-Chaves E, Cárdaba B, Martin-Orozco E, Posada M, Palomino P, Lahoz C (1995) Improved method for mRNA extraction from paraffin-embedded tissues. Biotechniques 18(1): 42–43.PubMedGoogle Scholar
  5. Gallardo S, del Pozo V, Cárdaba B, de Andrés B, Martin-Orozco E, Fernandez JC, Tramón P, Posada M, Abaitua I, Palomino P, Lahoz C (1994) Immunological basis of toxic oil syndrome (TOS). Toxicology 93:289–299.PubMedCrossRefGoogle Scholar
  6. Gleichmann H, Gleichman E (1984) GVHD a model for the Spanish Toxic Oil Syndrome. Lancet, i: 1174–1175.Google Scholar
  7. Goldman M, Druet P, Gleichmann E (1991) Th2 cells in systemic autoimmunity: insights from allogeneic diseases and chemically-induced autoimmunity. Immunol. Today 12(7): 223–227.PubMedCrossRefGoogle Scholar
  8. Greenberg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson D I (1988) Elevated levels of soluble IL-2 receptors in Multiple Sclerosis. New Eng. J. Med. 319:1019–1020.PubMedGoogle Scholar
  9. Kammüller M E, Penninks A H, Seinen W (1984) Spanish Toxic Oil Syndrome is a chemically induced graft-versus-host-like epidemic. Lancet, i: 1174–1175.CrossRefGoogle Scholar
  10. Kammüller M E, Bloksma N, Seinen W (1988) Chemically induced autoimmune reactions and Spanish toxic oil Syndrome. Focus on hydantoins and related compounds. J. Toxicol. 26:157–174.Google Scholar
  11. Kammüller ME., Bloksma N, Seinen W. (1989) Autoimmunity and toxicology. Immune dysregulation induced by drugs and chemicals. In: Kammüller M.E., Bloksma, N. and Seinen, W. (eds), Autoimmunity and toxicology. Immune dysregulation induced by drugs and chemicals. Elsevier, Amsterdam, pp 4–34.Google Scholar
  12. Kapsenberg ML, Wierenga EA, Bos JD, Jansen HM (1991) Functional subsets of allergen-reactive human CD4+ T cells. Immunol. Today 12(11): 392–395.PubMedCrossRefGoogle Scholar
  13. Kapsenberg ML, Jansen HM, Bos JD, Wierenga E A (1992) Role of type 1 and type 2 T helper cells in allergic diseases. Curr. Opin. Immunol. 4: 788–793.PubMedCrossRefGoogle Scholar
  14. Kaufman LD, Gruber BL, Gómez-Reino JJ, Miller F (1994) Fibrogenic growth factors in the eosinophilia-myalgia syndrome and the toxic oil syndrome. Arch. Dermatol 130: 41–47.PubMedCrossRefGoogle Scholar
  15. Kilbourne EM (1983) Clinical epidemiology of toxic oil syndrome. New. Engl. J. Med. 309: 1408–1414.PubMedCrossRefGoogle Scholar
  16. Kilbourne EM, Bernert JT, Posada M et al. (1988) Chemical correlates of the pathogenicity of oils related to the TOS epidemic in Spain. Am. J. Epidemiol. 127: 1210–1227.PubMedGoogle Scholar
  17. Kilbourne EM, Posada M, Abaitua I, et al. (1991) Toxic Oil Syndrome: A current clinical and epidemiologic summary, including comparisons with the eosinophilia-myalgia syndrome. J. Am. Coll. Cardiol. 18: 711–717.PubMedCrossRefGoogle Scholar
  18. Lahoz C, Tricas L, Vela C, Lauzurica P, Gurbindo C, Garcia R (1983) Hyper IgE, eosinophilia and immunological hyperreactivity due to ingestion of adultered rapeseed oil (Toxic Oil Syndrome). Eur. J. Respir. Dis. 62: 415–418.Google Scholar
  19. Lahoz C, Rose NR, Robinson CJG (1992) Immunology. In: Nadal, J and Tarkowski, S (Eds), “Toxic Oil Syndrome: current Knowledge and future perspectives”. WHO Regional Publications, European series, no 42, pp. 143–152.Google Scholar
  20. Lassalle P, Sergant M, Delneste Y, et al. (1991) Levels of soluble IL-2 receptor in plasma from asthmatics. Correlation blood eosinophilia, lung functions, and corticosteroid therapy. Clin. exp. Immunol. 87: 266–271.CrossRefGoogle Scholar
  21. Martínez Tello FJ, Téllez Y (1992) Pathology In: Nadal, J. and Tarkowski, S. (Eds), “Toxic Oil Syndrome: current Knowledge and future perspectives”. WHO Regional Publications, European series, no 42, pp. 39–65.Google Scholar
  22. Manoussakis MN, Papadoppulos GK, Drosos AA, Motsopoulos HM (1989) Soluble interleukin 2 receptor molecules in the serum of patients with autoimmune disease. Clin. Immunol. Immunopathol. 50:321–32.PubMedCrossRefGoogle Scholar
  23. Mayeno AN, Belongia EA, Fengling Lundu SK, Gleich GJ (1992) 3-(Phenyl-amino) alanine, a novel aniline-derived aminoacid associated with the Eosinophilia-Myalgia Syndrome: a link to the Toxic Oil Syndrome?. Mayo Clin. Proc. 67:1134–1139.PubMedGoogle Scholar
  24. McKinley KL, Harati Y, Schneider LW (1993) Chronic immune activation in the eosinophilia-myalgia syndrome. Muscle & Nerve 16: 947–951.CrossRefGoogle Scholar
  25. Romagnani S. (1991) Human Th1 and Th2 subsets: doubt no more. Immunol. Today. 12(8): 256–257.PubMedCrossRefGoogle Scholar
  26. Scott P, Kaufmann HE (1991) The role of T-cell subsets and cytokines in the regulation of infection. Immunol. Today. 12(10): 346–348.PubMedCrossRefGoogle Scholar
  27. Silverman ED, Laxer R, Nelson DL, Rubin L A (1991) Soluble interleukin 2 receptor in juvenile rheumatoid arthritis. J. Rheumatol. 18: 1398–1402.PubMedGoogle Scholar
  28. Tokano Y, Murashima A, Takasaki Y, Hashimoto H, Okomura K, Hirose S (1989) Relation between soluble interleukin 2 receptor and clinical findings in patients with systemic lupus erythematosus. Annals of Rheumatic Diseases 48: 803–809.CrossRefGoogle Scholar
  29. Tricas, L. (1984) “Immunological hyperreactivity in the acute phase of TOS” Doctoral Thesis, University of Zaragoza.Google Scholar
  30. WHO (1991) “Toxic oil syndrome and eosinophilia-myalgia syndrome. Pursuing parallels in pathogenesis”. Report on a WHO meeting, Washington, DC., WHO Regional Office for Europe, Copenhagen, 22 pp.Google Scholar
  31. WHO (1992) “Toxic oil syndrome and eosinophilia-myalgia syndrome. Clinical aspects”. Report on a workshop. Stony Brook, New York. WHO Regional Office for Europe, Copenhagen, 19 pp.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • Carlos Lahoz
    • 1
  • Victoria del Pozo
    • 1
  • Soledad Gallardo
    • 1
  • Blanca Cárdaba
    • 1
  • Aurora Jurado
    • 1
  • Isabel Cortegano
    • 1
  • Ana del Amo
    • 1
  • Ignacio Arrieta
    • 1
  • Pilar Palomino
    • 1
  1. 1.Immunology DepartmentFundación Jiménez DíazMadridSpain

Personalised recommendations